Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain

  Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic
  Neuropathic Pain

              -Company to Discontinue Z160 Clinical Development-

Business Wire

CAMBRIDGE, Mass. -- November 11, 2013

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced top-line results from two Phase 2 clinical studies of Z160 in
chronic pain indications. Z160 did not meet the primary endpoint in either of
the Phase 2 clinical studies in patients with lumbosacral radiculopathy (LSR)
and post-herpetic neuralgia (PHN). Z160 was shown to be generally safe and
well-tolerated with no drug-related serious adverse events. Based on these
results, Zalicus is discontinuing the Z160 program and plans to focus efforts
on Z944, its novel oral T-type calcium channel modulator in development for
the treatment of pain.

“Despite its promising preclinical profile, Z160 was unable to translate those
results into clinical efficacy. A review of the data demonstrate that both
studies were conducted in a rigorous fashion and resulted in adequate exposure
of Z160, yet failed to demonstrate a difference in effect from placebo on any
endpoint,” said Mark H.N. Corrigan, MD, President and CEO of Zalicus. “There
is a significant unmet need for novel and effective non-opioid based pain
therapies, and it was our sincere hope that Z160, with its novel mechanism of
action, would offer the potential to provide relief to the millions of
patients who suffer from chronic neuropathic pain.”

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain and has entered into multiple revenue-generating collaborations
with large pharmaceutical companies relating to other products, product
candidates and drug discovery technologies. Zalicus applies its expertise in
the discovery and development of selective ion channel modulators and its
combination high throughput screening capabilities to discover innovative
therapeutics for itself and its collaborators in the areas of pain,
inflammation, oncology and infectious disease. To learn more about Zalicus,
please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidates Z160 and Z944, the Zalicus selective Ion channel modulation
technology and related preclinical product candidates and Zalicus’ other
business plans. These forward-looking statements about future expectations,
plans, objectives and prospects of Zalicus and its product candidates may be
identified by words like "believe," "expect," "may," "will," "should," "seek,"
“plan” or “could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the development and
regulatory approval of Zalicus’ product candidates, including risks relating
to formulation and clinical development of Z944, the ability of Zalicus to
initiate and successfully complete clinical trials of its product candidates,
the unproven nature of the Zalicus drug discovery technologies, the Company's
ability to obtain additional financing or funding for its research and
development, and those other risks that can be found in the "Risk Factors"
section of Zalicus' annual report on Form 10-K on file with the Securities and
Exchange Commission and the other reports that Zalicus periodically files with
the Securities and Exchange Commission. Actual results may differ materially
from those Zalicus contemplated by these forward-looking statements. These
forward-looking statements reflect management’s current views and Zalicus does
not undertake to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the date of
this release except as required by law.

(c) 2013 Zalicus Inc. All rights reserved.


Zalicus Inc.
Justin Renz, 617-301-7575
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.